The Naloxone market is estimated to witness high growth owing to increasing opioid addiction
The
Naloxone Market is estimated to be valued at US$ 1234.6 Mn in 2023 and is
expected to exhibit a CAGR of 10.%
over the forecast period 2023 to 2030, as highlighted in a new report published
by Coherent Market Insights.
Market Overview:
Naloxone
is an opioid antagonist used for the complete or partial reversal of opioid
overdose such as respiratory depression. It competes with opioids and rapidly
binds to the opioid receptors without activating them, effectively reversing
the effects of the opioids. It provides fast reversal of respiratory depression
and other effects of opioid overdose, allowing for proper breathing to be
restored.
Market key trends:
One
of the key trends contributing to the growth of the Naloxone
Market Size is the increasing prevalence of opioid overdose. According
to the Center for Disease Control and Prevention (CDC), more than 93,000 people
died due to drug overdose in 2020 in the United States, out of which majority
were related to synthetic opioids like fentanyl. The rising opioid addiction
and overdose cases have propelled the demand for easy to use nasal spray and
auto-injector forms of naloxone that can provide immediate reversal effect at
the time of need. The increasing awareness about opioid overdose emergency
response through naloxone administration is also fueling the growth of the
market.
Porter’s Analysis
Threat
of new entrants: The Naloxone market has high capital requirements and
regulations which make it difficult for new companies to enter the market.
Bargaining power of buyers: Buyers have moderate bargaining power as they have
a few existing companies to choose from for naloxone products. Bargaining power
of suppliers: Suppliers have moderate bargaining power due to the availability
of substitute raw materials and suppliers. Threat of new substitutes: There is
a low threat from substitutes as currently naloxone is considered the gold
standard for opioid overdose treatment. Competitive rivalry: Intense as major
companies compete for a share in the growing market.
SWOT Analysis
Strength:
Naloxone is easily administered and effective in reversing opioid overdoses.
Growing cases of opioid addiction and overdoses present a large market
opportunity.
Weakness: Requires prescription and administration by medical professionals.
Potential abuse of naloxone products.
Opportunity: Alternative delivery methods like auto-injectors and intranasal
sprays present new revenue streams. Emerging markets and government programs
expanding access.
Threats: Stringent regulations around opioids increase compliance costs. Patent
expiries of branded products allow generic competition.
Key Takeaways
The
global Naloxone market is expected to witness high growth, exhibiting CAGR of
10.% over the forecast period, due to increasing prevalence of opioid addiction
and overdoses. According to WHO, 4.7 million Americans aged 12 or older battled
a substance use disorder involving prescription opioids or heroin in 2020.
North America dominates the Naloxone market currently due to the high burden of
the opioid crisis and supportive initiatives to expand access. The Asia Pacific
region also shows high growth potential with developments to address growing
non-medical use of prescription drugs.
Key players operating in the Naloxone market are Viatris Inc., Opiant
Pharmaceuticals, Akorn Operating Company LLC, Pfizer, Inc., Novartis AG,
Indivior Plc., Emergent BioSolutions Inc., Amphastar Pharmaceuticals, Inc.,
Kern Pharma, S.L., Hikma Pharmaceuticals PLC, Mundipharma International
Limited, and Kaleo, Inc. Major players focus on developing innovative drug
delivery technologies and expanding geographic presence through collaborations.
Read Our More Blogs : https://www.dailyprbulletin.com/naloxone-market-forecast-outlook-trend-2023-2030/
Comments
Post a Comment